{"title":"Reevaluating ADHD and its First-Line Treatment: Insights from DSM-5-TR and Modern Approaches.","authors":"Yaakov Ophir","doi":"10.36131/cnfioritieditore20240507","DOIUrl":null,"url":null,"abstract":"<p><p>Is Attention Deficit Hyperactivity Disorder (ADHD) a \"brain disorder\"? Should it be managed regularly with stimulant drugs? This article critically examines the evolving biomedical discourse surrounding these questions through a close inspection of the latest edition of the influential psychiatric manual - the DSM-5-TR - as well as additional authoritative sources (e.g., previous DSM editions, consensus statements, FDA communications). The DSM-5-TR acknowledges that \"<i>no biological marker is diagnostic for ADHD</i>\" and that \"<i>meta-analyses of all neuroimaging studies do not show differences between individuals with ADHD and control subjects</i>.\" The authors of the DSM-5-TR, therefore, conclude that \"<i>until these issues are resolved, no form of neuroimaging can be used for diagnosis of ADHD</i>.\" These statements, along with biases in the neuroimaging literature and additional empirical evidence presented in the article, challenge popular myths about the neurobiological basis of ADHD. Similarly, common beliefs about the first-line treatment of ADHD with stimulant drugs are being increasingly questioned today. For instance, the DSM-5-TR's section on <i>Stimulant-Related Disorders</i> introduces a new diagnostic entity named: <i>Stimulant-Induced Mild Neurocognitive Disorder</i>. This addition aligns with a recent FDA Drug Safety Communication for \"<i>all prescription stimulants</i>,\" which highlights longstanding concerns regarding the safety of medications prescribed to millions of diagnosed individuals, primarily children. The FDA now mandates that \"<i>the Boxed Warning, FDA's most prominent warning, will describe the risks of misuse, abuse, addiction, and overdose</i>,\" emphasizing that such \"<i>misuse and abuse of prescription stimulants can result in overdose and death</i>.\" In light of these challenges to the biomedical discourse, this article offers a neurodiversity-oriented alternative. Using evolutionary principles and historical context, it argues that most cases of ADHD fall under the DSM's socio-philosophical category of \"<i>conflicts that are primarily between the individual and society</i>\" (similar to homosexuality, which was removed from the DSM in 1973), and are therefore \"<i>not mental disorders</i>\".</p>","PeriodicalId":46700,"journal":{"name":"Clinical Neuropsychiatry","volume":"21 5","pages":"436-443"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555658/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36131/cnfioritieditore20240507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Is Attention Deficit Hyperactivity Disorder (ADHD) a "brain disorder"? Should it be managed regularly with stimulant drugs? This article critically examines the evolving biomedical discourse surrounding these questions through a close inspection of the latest edition of the influential psychiatric manual - the DSM-5-TR - as well as additional authoritative sources (e.g., previous DSM editions, consensus statements, FDA communications). The DSM-5-TR acknowledges that "no biological marker is diagnostic for ADHD" and that "meta-analyses of all neuroimaging studies do not show differences between individuals with ADHD and control subjects." The authors of the DSM-5-TR, therefore, conclude that "until these issues are resolved, no form of neuroimaging can be used for diagnosis of ADHD." These statements, along with biases in the neuroimaging literature and additional empirical evidence presented in the article, challenge popular myths about the neurobiological basis of ADHD. Similarly, common beliefs about the first-line treatment of ADHD with stimulant drugs are being increasingly questioned today. For instance, the DSM-5-TR's section on Stimulant-Related Disorders introduces a new diagnostic entity named: Stimulant-Induced Mild Neurocognitive Disorder. This addition aligns with a recent FDA Drug Safety Communication for "all prescription stimulants," which highlights longstanding concerns regarding the safety of medications prescribed to millions of diagnosed individuals, primarily children. The FDA now mandates that "the Boxed Warning, FDA's most prominent warning, will describe the risks of misuse, abuse, addiction, and overdose," emphasizing that such "misuse and abuse of prescription stimulants can result in overdose and death." In light of these challenges to the biomedical discourse, this article offers a neurodiversity-oriented alternative. Using evolutionary principles and historical context, it argues that most cases of ADHD fall under the DSM's socio-philosophical category of "conflicts that are primarily between the individual and society" (similar to homosexuality, which was removed from the DSM in 1973), and are therefore "not mental disorders".